PDCD1 and cancer: Cancer therapy has witnessed a paradigm shift with the advent of immune checkpoint inhibitors (ICIs), particularly cytotoxic T-lymphocyte activator-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) inhibitors [1–4].